All articles tagged with #jennifer doudna
Jennifer Doudna's startup Aurora Therapeutics aims to scale personalized gene-editing treatments for rare diseases like PKU using CRISPR technology and a new FDA pathway that expedites approval for bespoke therapies based on limited patient data.
The US Department of Energy's upcoming supercomputer 'Doudna', scheduled for 2026 and named after scientist Jennifer Doudna, will utilize Nvidia's Vera Rubin chips and Dell's liquid-cooled servers, serving 11,000 researchers at Lawrence Berkeley National Laboratory.
Nobel laureate Jennifer Doudna, a pioneer of CRISPR-Cas9 gene editing, emphasizes the need for more efficient and affordable delivery methods for CRISPR-based therapies, following the recent FDA approval of a sickle-cell therapy. The current process, involving bone marrow extraction and genetic engineering, is physically challenging and costly, limiting its widespread use. Doudna advocates for in vivo genome editing to address this bottleneck, highlighting ongoing efforts to develop nanoparticle delivery systems. She remains confident that solving the delivery challenge will unlock the immense potential of gene editing to alleviate human suffering.
"SaveGood Chemistry" is a documentary highlighting the work of Emmanuelle Charpentier and Jennifer Doudna, the first all-female team to win the Nobel Prize for chemistry in 2020 for their groundbreaking CRISPR gene-editing discovery. The film delves into the years of experimentation and collaboration that led to their landmark 2012 paper on the CRISPR system, offering insight into the biochemistry behind CRISPR and the experience of contributing to a world-changing scientific breakthrough.
Scientists have developed enveloped delivery vehicles (EDVs) that can transport CRISPR genome editing tools to specific cells for precise genome engineering within living organisms. These EDVs, created by Nobel Prize winner Jennifer Doudna's lab, have the potential for widespread therapeutic use and were shown to successfully target and edit the genomes of human cells in both in vitro and in vivo experiments. The research establishes a programmable delivery method for genome editing and highlights the potential for targeted in vivo engineering of tissue-resident stem cells.
Jennifer Doudna's lab published a study detailing how antibody fragments can target virus-like particles with gene editing machinery to T cells, co-founding genetic medicine delivery startup Azalea Therapeutics, which has raised $10 million.